Venous thromboembolism and malignancy

Expert Review of Anticancer Therapy

Volumn 4, Issue 2, 2004, Pages 303-320

  Gao, Shuwei ^a   Escalante, Carmen ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Deep vein thrombosis; Malignancy; Pulmonary embolism; thrombosis

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; AROMATASE INHIBITOR; ARZOXIFENE; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 9A; CYTOTOXIC AGENT; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NATROPARIN; PLACEBO; PROTEIN C; RALOXIFENE; REVIPARIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; THALIDOMIDE; THROMBIN INHIBITOR; THROMBOPLASTIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

BLEEDING; BLOOD CLOT LYSIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CENTRAL VENOUS CATHETERIZATION; CLINICAL STUDY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; EMBOLECTOMY; FOOD DRUG INTERACTION; HUMAN; HYPERCOAGULABILITY; INCIDENCE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM;

EID: 1842689550     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.2.303     Document Type: Review

References (183)

1. Donati MB. Cancer and thrombosis: From Phlegmasia alba dolens to transgenic mice. Thromb. Haemost. 74(1), 278-281 (1995).
2. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol. Oncol. Clin. North Am. 10(2), 499-530 (1996).
3. Hansson PO, Welin L, Tibblin G et al. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch. Intern. Med. 157(15), 1665-1670 (1997).
4. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. 151(5), 933-938 (1991).
5. Nordstrom M, Lindblad B, Bergqvist D et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J. Intern. Med. 232(2), 155-160 (1992).
6. Sorensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343(25), 1846-1850 (2000).
7. Levitan N, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78(5), 285-291 (1999).
8. Peuscher FW. Thrombosis and bleeding in cancer patients. Neth. J. Med. 24(1), 23-35 (1981).
9. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch. Intern. Med. 160(6), 809-815 (2000).
10. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90(18), 1371-1388 (1998).
11. Gail MH, Costantino JP, Bryant J et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl Cancer Inst. 91(21), 1829-1846 (1999).
12. Levine MN, Gent M, Hirsh J et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N. Engl. J. Med. 318(7), 404-407 (1988).
13. Goodnough LT, Saito H, Manni A et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 54(7), 1264-1268 (1984).
14. Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125(1), 1-7 (1996).
15. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. Arch. Intern. Med. 160(6), 769-774 (2000).
16. Douketis JD, Foster GA. Crowther MA et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch. Intern. Med. 160(22), 3431-3436 (2000).
17. Palareti G, Legnani C, Lee A et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb. Haemost. 84(5), 805-810 (2000).
18. Prandoni P, Villalta S, Polistena P et al. Symptomatic deep-vein thrombosis and the post-thrombotic syndrome. Haematologica 80(2 Suppl.), 42-48 (1995).
19. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 106(1-2), 6-12 (2001).
20. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62(1), 14-31 (1983).
21. Escalante CP, Kurtin D, Rivera E et al. Severity of illness, outcomes and resource use in elderly cancer patients with deep venous thrombosis. Clin. Appl. Thromb. Hemost. 6(3), 175-178 (2000).
22. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. J. Med. 334(11), 677-681 (1996).
23. Kakkar AK, Levine M, Pinedo HM et al. Venous thrombosis in cancer patients: Insights from the FRONTLINE survey. Oncologist 8(4), 381-388 (2003).
24. Sallah S, Wan J, Nguyen N. Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb. Haemost. 87(4), 575-579 (2002).
25. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin. Oncol. (R. Coll. Radiol.) 11(2), 105-110 (1999).
26. Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl Cancer Inst. 89(22), 1673-1682 (1997).
27. Sue-Ling HM, Johnston D, McMahon MJ et al. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1(8491), 1173-1176 (1986).
28. Huber O, Bounameaux H, Borst F et al. Postoperative pulmonary embolism after hospital discharge. An underestimated risk Arch. Surg. 127(3), 310-313 (1992).
29. Pritchard KI, Paterson AH, Paul NA et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J. Clin. Oncol. 14(10), 2731-2737 (1996).
30. von Tempelhoff GF, Dietrich M, Hommel G et al. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J. Clin. Oncol. 14(9), 2560-2568 (1996).
31. Weijl NI, Rutten MF, Zwinderman AH et al. Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature. J. Clin. Oncol. 18(10), 2169-2178 (2000).
32. Ottinger H, Belka C, Kozole G et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non-Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur. J. Haematol. 54(3), 186-194 (1995).
33. von Tempelhoff GF, Dietrich M, Niemann F et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb. Haemost. 77(3), 456-461 (1997).
34. Quevedo JF, Buckner JC, Schmidt JL et al. Thromboembolism in patients with high-grade glioma. Mayo Clin. Proc. 69(4), 329-332 (1994).
35. Pihusch R, Danzl G, Scholz M et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 94(12), 3120-3126 (2002).
36. Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch. Intern. Med. 160(6), 761-768 (2000).
37. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98(5), 1614-1615 (2001).
38. Desai AA, Vogelzang NJ, Rini BI et al. A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly iv. gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95(8), 1629-1636 (2002).
39. Horne MK III, Figg WD, Arlen P et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 23(3), 315-318 (2003).
40. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360(9336), 817-824 (2002).
41. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281(23), 2189-2197 (1999).
42. Burke TW, Walker CL. Arzoxifene as therapy for endometrial cancer. Gynecol. Oncol. 90(2 Pt 2), S40-S46 (2003).
43. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359(9324), 2131-2139 (2002).
44. Barbui T, Finazzi G, Grassi A et al. Thrombosis in cancer patients treated with hematopoietic growth factors: A meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 75(2), 368-371 (1996).
45. Beck C, Dubois J, Grignon A et al. Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: A prospective study. J. Pediatr. 133(2), 237-241 (1998).
46. Bern MM, Lokich JJ, Wallach SR et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann. Intern. Med. 112(6), 423-428 (1990).
47. Balestreri L, De Cicco M, Matovic M et al. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: A phlebographic study. Eur. J. Radiol. 20(2), 108-111 (1995).
48. Black MD, French GJ, Rasuli P et al. Upper extremity deep venous thrombosis. Underdiagnosed and potentially lethal. Chest 103(6), 1887-1890 (1993).
49. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin. Thromb. Hemost. 25(2), 173-182 (1999).
50. Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin. Thromb. Hemost. 25(2), 167-172 (1999).
51. Kakkar AK, DeRuvo N, Chinswangwatanakul V et al. Extrinsic-pathway activation in cancer with high Factor VIIa and tissue factor. Lancet 346(8981), 1004-1005 (1995).
52. Iversen LH, Okholm M, Thorlacius-Ussing O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease: A preliminary study. Thromb. Haemost. 76(4), 523-528 (1996).
53. Falanga A, Consonni R, Marchetti M et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 92(1), 143-151 (1998).
54. Hamada K, Kuratsu J, Saitoh Y et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 77(9), 1877-1883 (1996).
55. Rucinska M, Furman M, Skrzydlewski Z et al. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. Acta Biochim. Pol. 44(1), 109-112 (1997).
56. Gordon SG. A proteolytic procoagulant associated with malignant transformation. J. Histochem. Cytochem. 29(3A Suppl.), 457-463 (1981).
57. Saito T, Koyama T, Nagata K et al. Anticoagulant effects of retinoic acids on leukemia cells. Blood 87(2), 657-665 (1996).
58. Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 72(1), 128-133 (1988).
59. De Lucia D, De Vita F, Orditura M et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: Evidence for an acquired resistance to activated protein C. Tumori 83(6), 948-952 (1997).
60. Blann AD, Gurney D, Wadley M et al. Increased soluble P-selectin in patients with haematological and breast cancer: A comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul. Fibrinolysis 12(1), 43-50 (2001).
61. Hara Y, Steiner M, Baldini MG. Characterization of the platelet-aggregating activity of tumor cells. Cancer Res. 40(4), 1217-2122 (1980).
62. Ramacciotti E, Wolosker N, Puech-Leao P et al. Prevalence of Factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb. Res. 109(4), 171-174 (2003).
63. Fareed J, Hoppensteadt D, Lietz H et al. Malignancy-related thrombotic state is independent of defects in Factor V Leiden, prothrombin 20210 and MTHFR. Results from the initial profiling of cancer patients entering in a secondary prevention of venous thrombosis with enoxaparin (ONCENOX). J. Thromb. Haemost. 1(Suppl.) (2003) (Abstract P0848).
64. Balkwill F, Osborne R, Burke F et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 2(8570), 1229-1232 (1987).
65. Nawroth PP, Bank I, Handley D et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1. J. Exp. Med. 163(6), 1363-1375 (1986).
66. Pober JS. TNF as an activator of vascular endothelium. Ann. Inst. Pasteur Immunol. 139(3), 317-323 (1988).
67. Dvorak HF. Thrombosis and cancer. Hum. Pathol. 18(3), 275-284 (1987).
68. Doll DC, List AF, Greco FA et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann. Intern. Med. 105(1), 48-51 (1986).
69. Kahn SR, Joseph L, Abenhaim L et al. Clinical prediction of deep vein thrombosis in patients with leg symptoms. Thromb. Haemost. 81(3), 353-357 (1999).
70. Piccioli A, Prandoni P, Goldhaber SZ. Epidemiologic characteristics, management and outcome of deep venous thrombosis in a tertiary-care hospital: The Brigham and Women's Hospital DVT registry. Am. Heart J. 132(5), 1010-1014 (1996).
71. Meignan M, Rosso J, Gauthier H et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch. Intern. Med. 160(2), 159-164 (2000).
72. Lee AY, Julian JA, Levine MN et al. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann. Intern. Med. 131(6), 417-423 (1999).
73. Ten Wolde M, Kraaijenhagen RA, Prins MH et al. The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. Arch. Intern. Med. 162(16), 1880-1884 (2002).
74. Bates SM, Grand'Maison A, Johnston M et al. A latex D-dimer reliably excludes venous thromboembolism. Arch. Intern. Med. 161(3), 447-453 (2001).
75. Wells PS, Anderson DR, Bormanis J et al. Application of a diagnostic clinical model for the management of hospitalized patients with suspected deep-vein thrombosis. Thromb. Haemost. 81(4), 493-497 (1999).
76. Aschwanden M, Labs KH, Jeanneret C et al. The value of rapid D-dimer testing combined with structured clinical evaluation for the diagnosis of deep vein thrombosis. J. Vasc. Surg. 30(5), 929-935 (1999).
77. Anderson DR, Wells PS. Improvements in the diagnostic approach for patients with suspected deep vein thrombosis or pulmonary embolism. Thromb. Haemost. 82(2), 878-886 (1999).
78. Shields GP, Turnipseed S, Panacek EA et al. Validation of the Canadian clinical probability model for acute venous thrombosis. Acad. Emerg. Med. 9(6), 561-566 (2002).
79. Heijboer H, Buller HR, Lensing AW et al. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic out-patients. N. Engl. J. Med. 329(19), 1365-1369 (1993).
80. Lensing AW, Prandoni P, Brandjes D et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N. Engl. J. Med. 320(6), 342-345 (1989).
81. Davidson BL, Elliott CG, Lensing AW. Low accuracy of color Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. The RD Heparin Arthroplasty Group. Ann. Intern. Med. 117(9), 735-738 (1992).
82. Rose SC, Zwiebel WJ, Nelson BD et al. Symptomatic lower extremity deep venous thrombosis: Accuracy, limitations and role of color duplex flow imaging in diagnosis. Radiology 175(3), 639-644 (1990).
83. Hull R, Hirsh J, Sackett DL et al. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. Circulation 64(3), 622-625 (1981).
84. Cogo A, Lensing AW, Koopman MM et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: Prospective cohort study. Br. Med. J. 316(7124), 17-20 (1998).
85. Heijboer H, Jongbloets LM, Buller HR et al. Clinical utility of real-time compression ultrasonography for diagnostic management of patients with recurrent venous thrombosis. Acta Radiol. 33(4), 297-300 (1992).
86. Hull R, Taylor DW, Hirsh J et al. Impedance plethysmography: the relationship between venous filling and sensitivity and specificity for proximal vein thrombosis. Circulation 58(5), 898-902 (1978).
87. Keefe DL, Roistacher N, Pierri MK. Evaluation of suspected deep venous thrombosis in oncologic patients. Angiology 45(9), 771-775 (1994).
88. Huisman MV, Buller HR, ten Cate JW. Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. Arch. Intern. Med. 148(3), 681-683 (1988).
89. Mangkharak J, Chiewvit S, Chaiyasoot W et al. Radionuclide venography in the diagnosis of deep vein thrombosis of the lower extremities: A comparison to contrast venography. J. Med. Assoc. Thai. 81(6), 432-441 (1998).
90. Taillefer R, Edell S, Innes G et al. Acute thromboscintigraphy with (99m)Tc-apcitide: Results of the Phase III multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators. J. Nucl. Med. 41(7), 1214-1223 (2000).
91. Erdman WA, Jayson HT, Redman HC et al. Deep venous thrombosis of extremities: Role of MR imaging in the diagnosis. Radiology 174(2), 425-431 (1990).
92. Carpenter JP, Holland GA, Baum RA et al. Magnetic resonance venography for the detection of deep venous thrombosis: Comparison with contrast venography and duplex Doppler ultrasonography. J. Vasc. Surg. 18(5), 734-741 (1993).
93. Moody AR, Pollock JG, O'Connor AR et al. Lower-limb deep venous thrombosis: Direct MR imaging of the thrombus. Radiology 209(2), 349-355 (1998).
94. Prospective Investigation of Pulmonary Embolism Diagnosis Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 263(20), 2753-2759 (1990).
95. Hull RD, Raskob GE, Ginsberg JS et al. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch. Intern. Med. 154(3), 289-297 (1994).
96. Stein PD, Hull RD, Pineo G. Strategy that includes serial noninvasive leg tests for diagnosis of thromboembolic disease in patients with suspected acute pulmonary embolism based on data from PIOPED. Prospective Investigation of Pulmonary Embolism Diagnosis. Arch. Intern. Med. 155(19), 2101-2014 (1995).
97. Tillie-Leblond I, Mastora I, Radenne F et al. Risk of pulmonary embolism after a negative spiral CT angiogram in patients with pulmonary disease: 1-year clinical follow-up study. Radiology 223(2), 461-467 (2002).
98. Kim KI, Muller NL, Mayo JR. Clinically suspected pulmonary embolism: Utility of spiral CT. Radiology 210(3), 693-697 (1999).
99. Mullins MD, Becker DM, Hagspiel KD et al. The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism. Arch. Intern. Med. 160(3), 293-298 (2000).
100. Meaney JF, Weg JG, Chenevert TL et al. Diagnosis of pulmonary embolism with magnetic resonance angiography. N. Engl. J. Med. 336(20), 1422-1427 (1997).
101. Hull RD, Raskob GE, Brant RF et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch. Intern. Med. 157(22), 2562-2568 (1997).
102. Weitz JI. Low-molecular-weight heparins. N. Engl. J. Med. 337(10), 688-698 (1997).
103. Hirsh J, Warkentin TE, Raschke R et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 114(5 Suppl.), 489S-510S (1998).
104. Kakkar VV, Hoppenstead DA, Fareed J et al. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 99(6), 1965-1970 (2002).
105. Breddin HK, Hach-Wunderle V, Nakov R et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N. Engl. J. Med. 344(9), 626-631 (2001).
106. Hull RD, Raskob GE, Brant RF et al Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch. Intern. Med. 160(2), 229-236 (2000).
107. Dolovich LR, Ginsberg JS, Douketis JD et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type and dosing frequency. Arch. Intern. Med. 160(2), 181-188 (2000).
108. Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N. Engl. J. Med. 337(10), 657-662 (1997).
109. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous iv. heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 326(15), 975-982 (1992).
110. Prandoni P, Lensing AW, Buller HR et al. Comparison of sc. low-molecular-weight heparin with iv. standard heparin in proximal deep-vein thrombosis. Lancet 339(8791), 441-445 (1992).
111. Lindmarker P, Holmstrom M, Granqvist S et al. Comparison of once-daily sc. fragmin with continuous iv. unfractionated heparin in the treatment of deep vein thrombosis. Thromb. Haemost. 72(2), 186-190 (1994).
112. Koopman MM, Prandoni P, Piovella F et al. Treatment of venous thrombosis with iv. unfractionated heparin administered in the hospital as compared with sc. low-molecular-weight heparin administered at home. The Tasman Study Group. N. Engl. J. Med. 334(11), 682-687 (1996).
113. Fiessinger JN, Lopez-Fernandez M, Gatterer E et al. Once-daily sc. dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb. Haemost. 76(2), 195-199 (1996).
114. Luomanmaki K, Grankvist S, Hallert C et al. A multicentre comparison of once-daily sc. dalteparin (low molecular weight heparin) and continuous iv. heparin in the treatment of deep vein thrombosis. J. Intern. Med. 240(2), 85-92 (1996).
115. Simonneau G, Sors H, Charbonnier B et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N. Engl. J. Med. 337(10), 663-669 (1997).
116. Merli G, Spiro TE, Olsson CG et al. Subcutaneous enoxaparin once or twice daily compared with iv. unfractionated heparin for treatment of venous thromboembolic disease. Ann. Intern. Med. 134(3), 191-202 (2001).
117. Lensing AW, Prins MH, Davidson BL et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch. Intern. Med. 155(6), 601-607 (1995).
118. Siragusa S, Cosmi B, Piovella F et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am. J. Med. 100(3), 269-277 (1996).
119. Gould MY, Dembitzer AD, Doyle RL et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 130(10), 800-809 (1999).
120. Harrison L, McGinnis J, Crowther M et al. Assessment of out-patient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch. Intern. Med. 158(18), 2001-2003 (1998).
121. Wells PS, Kovacs MJ, Bormanis J et al. Expanding eligibility for out-patient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection. Arch. Intern. Med. 158(16), 1809-1812 (1998).
122. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin vs. warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch. Intern. Med. 157(3), 298-303 (1997).
123. Gould MK, Dembitzer AD, Sanders GD et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann. Intern. Med. 130(10), 789-799 (1999).
124. Ageno W, Steidl L, Marchesi C et al. Selecting patients for home treatment of deep vein thrombosis: The problem of cancer. Haematologica 87(3), 286-291 (2002).
125. Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: A meta-analysis. Thromb. Haemost. 86(4), 980-984 (2001).
126. Weiss P, Soff GA, Halkin H et al. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb. Res. 45(6), 783-790 (1987).
127. Kovacs MJ, Rodger M, Anderson DR et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for out-patient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann. Intern. Med. 138(9), 714-719 (2003).
128. Crowther MA, Ginsberg JB, Kearon C et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch. Intern. Med. 159(1), 46-48 (1999).
129. Harrison L, Johnston M, Massicotte MP et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann. Intern. Med. 126(2), 133-136 (1997).
130. Wester JP, de Valk HW, Nieuwenhuis HK et al. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb. Haemost. 76(5), 682-688 (1996).
131. Bona RD, Sivjee KY, Hickey AD et al. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb. Haemost. 74(4), 1055-1058 (1995).
132. Bona RD, Hickey AD, Wallace DM. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am. J. Clin. Oncol. 23(1), 71-73 (2000).
133. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J. Clin. Oncol. 18(17), 3078-3083 (2000).
134. Prandoni P, Villalta S, Bagatella P et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 82(4), 423-428 (1997).
135. Halkin H, Shapiro J, Kurnik D et al. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin. Pharmacol. Ther. 74(3), 215-221 (2003).
136. Witt DM, Tillman DJ, Evans CM et al. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program. Pharmacotherapy 23(3), 360-368 (2003).
137. Swenson CN, Fundak G. Observational cohort study of switching warfarin sodium products in a managed care organization. Am. J. Health Syst. Pharm 57(5), 452-455 (2000).
138. Weibert RT, Yeager BF, Wittkowsky AK et al. A randomized, crossover comparison of warfarin products in the treatment of chronic atrial fibrillation. Ann. Pharmacother. 34(9), 981-988 (2000).
139. Milligan PE, Banet GA, Waterman AD et al. Substitution of generic warfarin for coumadin in an HMO setting. Ann. Pharmacother. 36(5), 764-768 (2002).
140. Wilson SJ, Wells PS, Kovacs MJ et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: A randomized controlled trial. CMAJ 169(4), 293-298 (2003).
141. Monreal M, Roncales FJ, Ruiz J et al. Secondary prevention of venous thromboembolism: A role for low-molecular-weight heparin. Haemostasis 28(5), 236-243 (1998).
142. van der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism. Cochrane Database Syst. Rev. 1, CD002001 (2002).
143. Gonzalez-Fajardo JA, Arreba E, Castrodeza J et al. Venographic comparison of sc. low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J. Vasc. Surg. 30(2), 283-292 (1999).
144. Lopez-Beret P, Orgaz A, Fontcuberta J et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J. Vasc. Surg. 33(1), 77-90 (2001).
145. Lee AY, Levine MN, Baker RI etal. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349(2), 146-153 (2003).
146. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch. Intern. Med. 162(15), 1729-1735 (2002).
147. Lee AY, Julian JA, Levine MN et al. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: Results of a randomized trial in cancer patients with venous thromboembolism (VTE). Proc. Am. Soc. Clin. Oncol. 22, 211 (2003) (Abstract 846).
148. Harenberg J, Huhle G, Piazolo L et al. Long-term anticoagulation of out-patients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin. Thromb. Hemost. 23(2), 167-172 (1997).
149. Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer 80(4), 649-655 (1997).
150. Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340(12), 901-907 (1999).
151. Schulman S. For how long should the treatment with vitamin K antagonists be maintained? Haemostasis 29(Suppl. S1), 89-90 (1999).
152. AbuRahma AF, Stickler DL, Robinson PA. A prospective controlled study of the efficacy of short-term anticoagulation therapy in patients with deep vein thrombosis of the lower extremity. J. Vasc. Surg. 28(4), 630-637 (1998).
153. Pinede L, Duhaut P, Cucherat M et al. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: A meta-analysis of randomized, controlled trials. J. Intern. Med. 247(5), 553-562 (2000).
154. Schulman S, Granqvist S, Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N. Engl. J. Med. 336(6), 393-398 (1997).
155. Pinede L, Ninet J, Duhaut P et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103(20), 2453-2460 (2001).
156. Konstantinides S, Geibel A, Olschewski M et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry. Circulation 96(3), 882-888 (1997).
157. Mikkola KM, Patel SR, Parker JA et al. Attenuation over 24 h of the efficacy of thrombolysis of pulmonary embolism among patients with cancer. Am. Heart J. 134(4), 603-607 (1997).
158. Millward SF, Peterson RA, Moher D et al. LGM (Vena Tech) vena caval filter: Experience at a single institution. J. Vasc. Interv. Radiol. 5(2), 351-356 (1994).
159. Decousus H, Leizorovicz A, Parent F et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N. Engl. J. Med. 338(7), 409-415 (1998).
160. Schleich JM, Morla O, Laurent M et al. Long-term follow-up of percutaneous vena cava filters: A prospective study in 100 consecutive patients. Eur. J. Vasc. Endovasc. Surg. 21(5), 450-457 (2001).
161. Eriksson UG, Bredberg U, Gislen K et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur. J. Clin. Pharmacol. 59(1), 35-43 (2003).
162. Francis CW, Davidson BL, Berkowitz SD et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann. Intern. Med. 137(8), 648-655 (2002).
163. Schulman S, Wahlander K, Lundstrom T et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med. 349(18), 1713-1721 (2003).
164. Eriksson H, Wahlander K, Gustafsson D et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor
165. Eriksson BI, Bergqvist D, Kalebo P et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO II randomised trial. Lancet 360(9344), 1441-1447 (2002).
166. Francis CW, Berkowitz SD, Comp PC et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N. Engl. J. Med. 349(18), 1703-1712 (2003).
167. Huisman MV. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: A randomized, double-blind, multinational study. J. Thromb. Haemost. 1(Suppl.) (2003) (Abstract OC003).
168. Berkowitz SD, Marder VJ, Kosutic G et al. Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. J. Thromb. Haemost. 1(9), 1914-1919 (2003).
169. Kast CE, Guggi D, Langoth N et al. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm. Res. 20(6), 931-936 (2003).
170. Mismetti P, Laporte S, Darmon JY et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br. J. Surg. 88(7), 913-930 (2001).
171. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br. J. Surg. 84(8), 1099-1103 (1997).
172. Bergqvist D, Burmark US, Flordal PA et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br. J. Surg. 82(4), 496-501 (1995).
173. Agnelli G, Bolis G, Capussotti L et al. A clinical outcome-based prospective study on venous thromboembolism in cancer surgery: The ®ISTOS project. J. Thromb. Haemost. 1(Suppl.) (2003) (Abstract OC191).
174. Bergqvist D, Agnelli G, Cohen AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N. Engl. J. Med. 346(13), 975-980 (2002).
175. Mismetti P, Mille D, Laporte S et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: A pilot randomized trial. Haematologica 88(1), 67-73 (2003).
176. Monreal M, Alastrue A, Rull M et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with a low molecular weight heparin (Fragmin). Thromb. Haemost. 75(2), 251-253 (1996).
177. Verso M, Agnelli G, Bertoglio S et al. A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter. J. Thromb. Haemost. 1(Suppl.) (2003) (Abstract P0825).
178. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 119(1 Suppl.), 132S-175S (2001).
179. Levine M, Hirsh J, Gent M et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343(8902), 886-889 (1994).
180. Hettiarachchi RJ, Smorenburg SM, Ginsberg J et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb. Haemost. 82(2), 947-952 (1999).
181. Kakkar A, Levine MN, Kadziola Z et al. Low-molecular weight heparin therapy and survival inpatients with malignant disease. J. Thromb. Haemost. 1(Suppl.) (2003) (Abstract P0843).
182. Klerk CPW, Smorenburg SM, Otten JMMB et al. Malignancy and low-molecular-weight heparin therapy: The MALT trial. J. Thromb. Haemost. 1(Suppl.) (2003) (Abstract OC195).
183. Amirkhosravi A, Mousa SA, Amaya M et al. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J. Thromb. Haemost. 1(9), 1972-1976 (2003).